Indications

• Pulmonary Hypertension (see Pulmonary Hypertension, [[Pulmonary Hypertension]])
  • RCT of Macitentan in Symptomatic Pulmonary Hypertension (2013) [MEDLINE]: macitentan improves morbidity and mortality in pulmonary hypertension (this is unique, as other agents in the treatment of pulmonary hypertension have not been demonstrated to have mortality benefits)

---

Pharmacology

• Endothelin Receptor Antagonist (see Endothelin Receptor Antagonists, [[Endothelin Receptor Antagonists]])

Metabolism

• xxxx

---

Administration

• PO

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Neurologic Adverse Effects

• Headache (see Headache, [[Headache]])

Hematologic Adverse Effects

• Anemia (see Anemia, [[Anemia]])

Other Adverse Effects

• Nasopharyngitis (see Pharyngitis, [[Pharyngitis]])

---

References

• Safety, tolerability, pharmacokinetics and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple dose study in healthy subjects. J Clin Pharmacol 2013;53(11):1131-1138 [MEDLINE]
• Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917 [MEDLINE]